{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:21:24Z","timestamp":1794554484539,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,3,11]],"date-time":"2010-03-11T00:00:00Z","timestamp":1268265600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s11926-010-0085-2","type":"journal-article","created":{"date-parts":[[2010,3,10]],"date-time":"2010-03-10T05:44:14Z","timestamp":1268199854000},"page":"80-86","source":"Crossref","is-referenced-by-count":21,"title":["Remission in Juvenile Idiopathic Arthritis: Current Facts"],"prefix":"10.1007","volume":"12","author":[{"given":"Susan","family":"Shenoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,11]]},"reference":[{"key":"85_CR1","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/rheumatology\/41.12.1428","volume":"41","author":"JC Packham","year":"2002","unstructured":"Packham JC, Hall MA: Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002, 41:1428\u20131435.","journal-title":"Rheumatology (Oxford)"},{"key":"85_CR2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/rheumatology\/39.2.198","volume":"39","author":"M Zak","year":"2000","unstructured":"Zak M, Pedersen FK: Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford) 2000, 39:198\u2013204.","journal-title":"Rheumatology (Oxford)"},{"key":"85_CR3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0889-857X(21)00134-4","volume":"17","author":"CA Wallace","year":"1991","unstructured":"Wallace CA, Levinson JE: Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am 1991, 17:891\u2013905.","journal-title":"Rheum Dis Clin North Am"},{"key":"85_CR4","first-page":"2256","volume":"27","author":"K Minden","year":"2000","unstructured":"Minden K, Kiessling U, Listing J, et al.: Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol 2000, 27:2256\u20132263.","journal-title":"J Rheumatol"},{"key":"85_CR5","first-page":"1989","volume":"29","author":"K Oen","year":"2002","unstructured":"Oen K, Malleson PN, Cabral DA, et al.: Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002, 29:1989\u20131999.","journal-title":"J Rheumatol"},{"key":"85_CR6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/BOR.0b013e32832f142e","volume":"21","author":"P Woo","year":"2009","unstructured":"Woo P: Theoretical and practical basis for early aggressive therapy in paediatric autoimmune disorders. Curr Opin Rheumatol 2009, 21:552\u2013557.","journal-title":"Curr Opin Rheumatol"},{"key":"85_CR7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/ard.2007.073445","volume":"67","author":"M Bartoli","year":"2008","unstructured":"\u2022 Bartoli M, Taro M, Magni-Manzoni S, et al.: The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2008, 67:370\u2013374. This study demonstrated that favorable response to methotrexate in JIA helps predict improved long-term outcome.","journal-title":"Ann Rheum Dis"},{"key":"85_CR8","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/ard.2006.064717","volume":"66","author":"MA Rossum van","year":"2007","unstructured":"van Rossum MA, van Soesbergen RM, Boers M, et al.: Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 2007, 66:1518\u20131524.","journal-title":"Ann Rheum Dis"},{"key":"85_CR9","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/art.1780241012","volume":"24","author":"RS Pinals","year":"1981","unstructured":"Pinals RS, Masi AT, Larsen RA: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981, 24:1308\u20131315.","journal-title":"Arthritis Rheum"},{"key":"85_CR10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"AM Gestel van","year":"1996","unstructured":"van Gestel AM, Prevoo ML, van \u2019t Hof MA, et al.: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis Rheum 1996, 39:34\u201340.","journal-title":"Arthritis Rheum"},{"key":"85_CR11","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","volume":"49","author":"DM Heijde van der","year":"1990","unstructured":"van der Heijde DM, van \u2019t Hof MA, van Riel PL, et al.: Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990, 49:916\u2013920.","journal-title":"Ann Rheum Dis"},{"key":"85_CR12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/ard.51.2.177","volume":"51","author":"DM Heijde van der","year":"1992","unstructured":"van der Heijde DM, van \u2019t Hof MA, van Riel PL, et al.: Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992, 51:177\u2013181.","journal-title":"Ann Rheum Dis"},{"key":"85_CR13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van \u2019t Hof MA, Kuper HH, et al.: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44\u201348.","journal-title":"Arthritis Rheum"},{"issue":"6 Suppl 43","key":"85_CR14","first-page":"S33","volume":"24","author":"B Saleem","year":"2006","unstructured":"Saleem B, Nizam S, Emery P: Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol 2006, 24(6 Suppl 43):S33\u2013S36.","journal-title":"Clin Exp Rheumatol"},{"issue":"6 Suppl 43","key":"85_CR15","first-page":"S7","volume":"24","author":"JS Smolen","year":"2006","unstructured":"Smolen JS, Aletaha D: What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol 2006, 24(6 Suppl 43):S7\u2013S13.","journal-title":"Clin Exp Rheumatol"},{"issue":"6 Suppl 43","key":"85_CR16","first-page":"S1","volume":"24","author":"T Pincus","year":"2006","unstructured":"Pincus T, Kavanaugh A, Aletaha D, Smolen J: Complexities in defining remission in rheumatic diseases. Clin Exp Rheumatol 2006, 24(6 Suppl 43):S1\u2013S6.","journal-title":"Clin Exp Rheumatol"},{"key":"85_CR17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.semarthrit.2005.06.003","volume":"35","author":"CA Sesin","year":"2005","unstructured":"Sesin CA, Bingham CO 3rd: Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum 2005, 35:185\u2013196.","journal-title":"Semin Arthritis Rheum"},{"key":"85_CR18","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/ard.2005.037333","volume":"64","author":"H Makinen","year":"2005","unstructured":"Makinen H, Kautiainen H, Hannonen P, Sokka T: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005, 64:1410\u20131413.","journal-title":"Ann Rheum Dis"},{"key":"85_CR19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/art.11481","volume":"50","author":"ET Molenaar","year":"2004","unstructured":"Molenaar ET, Voskuyl AE, Dinant HJ, et al.: Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004, 50:36\u201342.","journal-title":"Arthritis Rheum"},{"key":"85_CR20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/rheumatology\/35.11.1101","volume":"35","author":"ML Prevoo","year":"1996","unstructured":"Prevoo ML, van Gestel AM, van \u2019t Hof MA, et al.: Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996, 35:1101\u20131105.","journal-title":"Br J Rheumatol"},{"key":"85_CR21","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/rheumatology\/keh297","volume":"43","author":"J Fransen","year":"2004","unstructured":"Fransen J, Creemers MC, Van Riel PL: Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004, 43:1252\u20131255.","journal-title":"Rheumatology (Oxford)"},{"key":"85_CR22","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/rheumatology\/kem007","volume":"46","author":"M Mierau","year":"2007","unstructured":"Mierau M, Schoels M, Gonda G, et al.: Assessing remission in clinical practice. Rheumatology (Oxford) 2007, 46:975\u2013979.","journal-title":"Rheumatology (Oxford)"},{"key":"85_CR23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/art.24392","volume":"61","author":"LH Tuyl van","year":"2009","unstructured":"van Tuyl LH, Vlad SC, Felson DT, et al.: Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology\/European League Against Rheumatism consensus conference. Arthritis Rheum 2009, 61:704\u2013710.","journal-title":"Arthritis Rheum"},{"key":"85_CR24","first-page":"2290","volume":"31","author":"CA Wallace","year":"2004","unstructured":"\u2022\u2022 Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group: Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004, 31:2290\u20132294. Original article, documenting preliminary criteria for remission in JIA.","journal-title":"J Rheumatol"},{"key":"85_CR25","first-page":"789","volume":"33","author":"CA Wallace","year":"2006","unstructured":"\u2022 Wallace CA, Ravelli A, Huang B, Giannini EH: Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. J Rheumatol 2006, 33:789\u2013795. Original study for validation of remission criteria in JIA.","journal-title":"J Rheumatol"},{"key":"85_CR26","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1002\/art.21389","volume":"52","author":"CA Wallace","year":"2005","unstructured":"\u2022 Wallace CA, Huang B, Bandeira M, et al.: Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005, 52:3554\u20133562. Retrospective study of JIA patients showing time spent in disease activity states.","journal-title":"Arthritis Rheum"},{"key":"85_CR27","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3899\/jrheum.080434","volume":"36","author":"A Lurati","year":"2009","unstructured":"Lurati A, Salmaso A, Gerloni V, et al.: Accuracy of Wallace criteria for clinical remission in juvenile idiopathic arthritis: a cohort study of 761 consecutive cases. J Rheumatol 2009, 36:1532\u20131535.","journal-title":"J Rheumatol"},{"key":"85_CR28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1590\/S0021-75572007000200008","volume":"83","author":"TA Fernandes","year":"2007","unstructured":"Fernandes TA, Corrente JE, Magalhaes CS: Remission status follow-up in children with juvenile idiopathic arthritis. J Pediatr (Rio J) 2007, 83:141\u2013148.","journal-title":"J Pediatr (Rio J)"},{"key":"85_CR29","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/rheumatology\/kep144","volume":"48","author":"S Ringold","year":"2009","unstructured":"Ringold S, Seidel KD, Koepsell TD, Wallace CA: Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) 2009, 48:972\u2013977.","journal-title":"Rheumatology (Oxford)"},{"key":"85_CR30","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3899\/jrheum.090952","volume":"36","author":"RA Russo","year":"2009","unstructured":"Russo RA, Katsicas MM: Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009, 36:1078\u20131082.","journal-title":"J Rheumatol"},{"key":"85_CR31","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.24202","volume":"59","author":"N Solari","year":"2008","unstructured":"Solari N, Viola S, Pistorio A, et al.: Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. Arthritis Rheum 2008, 59:1571\u20131579.","journal-title":"Arthritis Rheum"},{"key":"85_CR32","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/art.23916","volume":"59","author":"S Magni-Manzoni","year":"2008","unstructured":"Magni-Manzoni S, Ruperto N, Pistorio A, et al.: Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008, 59:1120\u20131127.","journal-title":"Arthritis Rheum"},{"key":"85_CR33","unstructured":"\u2022 Foell D, Wulffraat N, Wedderburn LR, et al.: Towards a risk-adapted therapy to maintain clinical remission in juvenile idiopathic arthritis: results of a randomized trial of 6 versus 12\u00a0months withdrawal of methotrexate. [abstract 551]. Presented at the American College of Rheumatology Annual Meeting. Philadelphia, PA; October 16\u201321, 2009. This study looked at duration of methotrexate therapy in ID to determine the risk of relapse. The study also used myeloid-related proteins as a biologic marker to determine the risk for flare in JIA."},{"key":"85_CR34","unstructured":"\u2022 Tynjala P, Vahasalo P, Tarkisinen M, et al.: Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (A-CUTE-JIA): a multicenter randomized clinical trial. [abstract 2051]. Presented at the American College of Rheumatology Annual Meeting. Philadelphia, PA; October 16\u201321, 2009. This abstract showed preliminary results from the A-CUTE-JIA, a study that compared three different treatment regimens used for JIA."},{"key":"85_CR35","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.24298","volume":"60","author":"N Knowlton","year":"2009","unstructured":"Knowlton N, Jiang K, Frank MB, et al.: The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononuclear cells identifies distinct disease states. Arthritis Rheum 2009, 60:892\u2013900.","journal-title":"Arthritis Rheum"},{"key":"85_CR36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10067-008-1057-z","volume":"28","author":"M Prelog","year":"2009","unstructured":"Prelog M, Schwarzenbrunner N, Tengg E, et al.: Quantitative alterations of CD8+ T cells in juvenile idiopathic arthritis patients in remission. Clin Rheumatol 2009, 28:385\u2013389.","journal-title":"Clin Rheumatol"},{"key":"85_CR37","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3899\/jrheum.080560","volume":"36","author":"A Magnani","year":"2009","unstructured":"\u2022 Magnani A, Pistorio A, Magni-Manzoni S, et al.: Achievement of a state of inactive disease at least once in the first 5\u00a0years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol 2009, 36:628\u2013634. This study showed that children with JIA who attain ID early on in their disease course tend to have less long-term joint damage.","journal-title":"J Rheumatol"},{"key":"85_CR38","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/art.24190","volume":"59","author":"T Beukelman","year":"2008","unstructured":"Beukelman T, Guevara JP, Albert DA: Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis. Arthritis Rheum 2008, 59:1580\u20131588.","journal-title":"Arthritis Rheum"},{"key":"85_CR39","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/art.20288","volume":"50","author":"N Ruperto","year":"2004","unstructured":"Ruperto N, Murray KJ, Gerloni V, et al.: A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004, 50:2191\u20132201.","journal-title":"Arthritis Rheum"},{"key":"85_CR40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/1529-0131(199803)41:3<381::AID-ART2>3.0.CO;2-3","volume":"41","author":"CA Wallace","year":"1998","unstructured":"Wallace CA: The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 1998, 41:381\u2013391.","journal-title":"Arthritis Rheum"},{"key":"85_CR41","first-page":"118","volume":"20","author":"CA Wallace","year":"1993","unstructured":"Wallace CA, Sherry DD, Mellins ED, Aiken RP: Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J Rheumatol 1993, 20:118\u2013122.","journal-title":"J Rheumatol"},{"key":"85_CR42","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1517\/14656560903386300","volume":"10","author":"A Klein","year":"2009","unstructured":"Klein A, Horneff G: Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother 2009, 10:3049\u20133060.","journal-title":"Expert Opin Pharmacother"},{"key":"85_CR43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/adc.2009.170860","volume":"94","author":"MW Beresford","year":"2009","unstructured":"Beresford MW, Baildam EM: New advances in the management of juvenile idiopathic arthritis\u20142. The era of biologicals. Arch Dis Child Educ Pract Ed 2009, 94:151\u2013156.","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"85_CR44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/ar2619","volume":"11","author":"K Hayward","year":"2009","unstructured":"Hayward K, Wallace CA: Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009, 11:216.","journal-title":"Arthritis Res Ther"},{"key":"85_CR45","doi-asserted-by":"crossref","unstructured":"Shenoi S, Wallace CA: TNF alpha inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs 2010 (in press).","DOI":"10.2165\/11532610-000000000-00000"},{"key":"85_CR46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"MA Quinn","year":"2005","unstructured":"Quinn MA, Conaghan PG, O\u2019Connor PJ, et al.: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a 12-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52:27\u201335.","journal-title":"Arthritis Rheum"},{"key":"85_CR47","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/art.11156","volume":"48","author":"M Boers","year":"2003","unstructured":"Boers M: Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003, 48:1771\u20131774.","journal-title":"Arthritis Rheum"},{"key":"85_CR48","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0002-9343(01)00973-1","volume":"111","author":"LW Moreland","year":"2001","unstructured":"Moreland LW, Bridges SL Jr: Early rheumatoid arthritis: a medical emergency? Am J Med 2001, 111:498\u2013500.","journal-title":"Am J Med"},{"key":"85_CR49","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/art.10092","volume":"46","author":"JR O\u2019Dell","year":"2002","unstructured":"O\u2019Dell JR: Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002, 46:283\u2013285.","journal-title":"Arthritis Rheum"},{"key":"85_CR50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/ard.2003.013961","volume":"63","author":"FC Breedveld","year":"2004","unstructured":"Breedveld FC, Emery P, Keystone E, et al.: Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004, 63:149\u2013155.","journal-title":"Ann Rheum Dis"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0085-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-010-0085-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0085-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T17:30:08Z","timestamp":1635096608000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-010-0085-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,11]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["85"],"URL":"https:\/\/doi.org\/10.1007\/s11926-010-0085-2","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,11]]}}}